Fertility services were significantly curtailed or suspended as an initial response to the coronavirus (COVID-19) pandemic earlier this year, following guidance from European Society for Human Reproduction and Embryology (ESHRE) and the American Society for Reproductive Medicine (ASRM) as well as a General Direction (GD0014) issued by the Human Fertilisation and Embryo Authority (HFEA). It is difficult to argue with triage of medical care and resources in the face of anticipated overwhelming demand, but this situation resulted in considerable distress, as shown by a change.org petition opposing ASRM recommendations, which has gathered over 21,000 signatures to date. Although halting assisted reproductive technology (ART) as the pandemic unfolded was ethical because public health goals superseded individual patient autonomy, the fertility sector now faces a greater challenge balancing ethical considerations in an era characterized by the ongoing threat of COVID-19. This article discusses justice and autonomy in the context of ART, potential conflicts and resolutions.

根据欧洲人类生殖与胚胎学学会（ESHRE）和美国生殖医学学会（ASRM）的指导，今年早些时候对冠状病毒（COVID-19）大流行的最初反应，生育服务显着减少或暂停。由人类受精和胚胎管理局（HFEA）发布的通用说明（GD0014）。面对预期的压倒性需求，很难对医疗和资源的分类进行争论，但是这种情况导致了相当大的困扰，正如change.org请愿书反对ASRM建议所表明的那样，迄今为止，ASRM建议已收集了超过21,000个签名。尽管随着大流行的发展而停止辅助生殖技术（ART）是符合道德的，因为公共卫生目标取代了患者的自主权，在以COVID-19持续威胁为特征的时代，当今的生育行业在平衡道德考量的同时面临着更大的挑战。本文讨论了抗逆转录病毒疗法，潜在冲突和解决方案下的正义与自治。